Auhtors: El-Benhawy SA, El-Sheredy HG, Ghanem HB, El-Soud AAA doi: https://doi.org/10.2217/bmt-2020-0007 Abstract Aim: Our objective was to investigate the effect of ionizing radiation (IR) and berberine on the expression of stem cell markers OCT4 and SOX2. Materials & methods: The study involved the following groups: Group I: MCF-7 spheroids as untreated control; Group II: MCF-7 [...]

Ivermectin was shown to inhibit severe acute respiratory syndrome coronavirus 2 replication in vitro, which has led to off-label use, but clinical efficacy has not been described previously.

Coronavirus disease 2019 (COVID-19) is sweeping the globe. Despite multiple case-series, actionable knowledge to tailor decision-making proactively is missing. Can a statistical model accurately predict infection with COVID-19?

Authors: Elharrar X, Trigui Y, Dois AM, Touchon F PMID: 32412581 PMCID: PMC7229532 DOI: 10.1001/jama.2020.8255 Abstract This case series describes the proportion of awake, nonintubated inpatients with COVID-19 and hypoxemic respiratory failure requiring oxygen supplementation whose Pao2 increased ≥20% with prone positioning, and their respiratory status after resuming supine positioning. Keywords: prone positioning, COVID-19, hypoxemic [...]

Authors: Liadet L, Szabo C DOI:10.1186/s13054-020-03055-6 Abstract The pulmonary renin angiotensin (Ang) system (RAS) comprises two pathways whose balance is important for lung homeostasis. Endothelial ACE generates Ang II, acting on AT1 receptors to promote vasoconstriction and pro-inflammatory effects, whereas epithelial ACE2 cleaves Ang II into Ang1–7, acting on the Mas receptor to exert vasodilatory [...]

Authors: Jouffroy R, Jost D, Prunet B PMID: 32513249 PMCID: PMC7278215 doi: 10.1186/s13054-020-03036-9 Abstract The COVID-19 pandemic, which has been expanding since the first cases in Asia in late 2019, may result in acute respiratory failure (ARF) with severe hypoxemia [1–3]. In prehospital settings, the paucity of clinical respiratory signs has made assessing the severity [...]

This Pilot clinical trial conducted on hospitalized adult patients with mild to moderate COVID-19 diagnosed according to WHO interim guidance. Sixteen Patients received a single dose of IVM 200Mcg /kg on admission day as add on therapy to hydroxychloroquine (HCQ)and Azithromycin (AZT) and were compared with 71 controls received HCQ and AZT matched in age, gender, clinical features, and comorbidities.

Authors: Poor HD, Ventetuolo CE, Tolbert T, Chun G, Serrao G PMID: 32508062 PMCID: PMC7288983 DOI: 10.1002/ctm2.44 Abstract Patients with severe COVID-19 disease have been characterized as having the acute respiratory distress syndrome (ARDS). Critically ill COVID-19 patients have relatively well-preserved lung mechanics despite severe gas exchange abnormalities, a feature not consistent with classical ARDS [...]

Authors: Janowitz T, Baglenz E, Pattinson D, Wang TC, Conigliaro J PMID: 32499303 PMCID: PMC7299656 DOI: 10.1136/gutjnl-2020-321852 Abstract Objective: Treatment options for non-hospitalised patients with coronavirus disease 2019 (COVID-19) to reduce morbidity, mortality and spread of the disease are an urgent global need. The over-the-counter histamine-2 receptor antagonist famotidine is a putative therapy for COVID-19. [...]

Authors: Guan W, Ni Z, Hu Y, Liang W, Ou C, He J PMCID: PMC7266766 doi: 10.1016/j.jemermed.2020.04.004 Abstract The novel coronavirus (SARS-CoV-2, causing COVID-19) was originally isolated in Wuhan, China. This virus spread quickly throughout many countries in Asia and now Europe, Australia, North America, leading the World Health Organization to declare COVID-19 a pandemic. [...]